Schering-Plough to develop Centocor arthritis treatment

Johnson & Johnson biotech subsidiary Centocor won backing from Schering-Plough on its developmental treatment for rheumatoid arthritis. In exercising previously acquired rights to jointly develop the drug, a monoclonal antibody, Schering-Plough is taking on $125 million in Centocor's previous R&D costs and will share future costs of getting the drug to market. In exchange, Schering-Plough will get some exclusive marketing rights, similar to its deal with Centocor on Remicade.

- read this AP story for more

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.